

**From:** [Abra Yeh](#)  
**To:** [HRSA Paperwork](#)  
**Subject:** [EXTERNAL] Re: Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program, OMB No. 0915-0327—Revision.  
**Date:** Sunday, October 5, 2025 10:33:42 PM  
**Attachments:** [Gilead Comment - HRSA ICR Grantees.pdf](#)

---

Dear HRSA Information Collection Clearance Officer,

Thank you for the opportunity to comment on HRSA's Information Collection Request regarding Enrollment and Re-Certification of Entities in the 340B Drug Pricing Program, including the ways in which HRSA can ensure more efficient program processes and greater program integrity under the 340B Program. Please find attached Gilead's comments.

We look forward to further dialogue on these issues. If you have any questions regarding Gilead's comments, or if we can provide any additional information, please contact Michelle Drozd at [michelle.drozd2@gilead.com](mailto:michelle.drozd2@gilead.com).

Sincerely,  
**Abra Yeh** | Government Affairs | [www.gilead.com](http://www.gilead.com)

**CAUTION:** This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and are confident the content is safe.